Ariadne Genomics Licenses PathwayStudio® to UCB to Support the Discovery of New Drug Targets and Biomarkers
Ariadne Genomics, Inc., today announced that UCB (Euronext: UCB) has licensed its PathwayStudio® software to support early stages of the drug discovery process – target identification and biomarker research.
UCB is a global biopharmaceutical leader with headquarters in Brussels, Belgium, specializing in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders, as well as oncology.
PathwayStudio comes with ResNet™ database of 500,000+ functional relationships and MedScan™ modules for automatic extraction of information from scientific literature. The software enables life science researchers to interpret their own discoveries in the context of biological pathways and gene regulation networks; it makes it easy to identify relationships among proteins, small molecules, cell processes and treatments, reconstruct pathways from microarray and proteomics data, identify biomarkers, and model drug responses.
“PathwayStudio being a client-server application offers pharmaceutical research groups easy and flexible team-wide access to the database, as well as the power of whole PubMed data at their fingertips”, commented Ilya Mazo, President of Ariadne Genomics.
More information about PathwayStudio, or a 20 day fully functional product trial, can be found on the Ariadne Genomics website www.ariadnegenomics.com.
About Ariadne Genomics
Ariadne Genomics develops systems biology software for life sciences research: PathwayStudio® (formerly known as PathwayAssist) and PathwayExpert™ pathway analysis software, MedScan Reader™ that comes with an automated scientific text processing algorithm, and a variety of molecular network databases. More on Ariadne Genomics please find at www.ariadnegenomics.com .
